不宁腿综合征治疗药物加巴喷丁恩那卡比  

Treatment of restless legs syndrome with gabapentin enacarbil

作　　者：樊梦林 解晓帅[2] 刘颖[3] 刘登科[3] 王平保[3] 

机构地区：[1]天津医科大学研究生院,天津300070 [2]天津市第一中心医院,天津300192 [3]天津药物研究院,天津市新药设计与发现重点实验室,天津300193

出　　处：《药物评价研究》2016年第3期501-504,共4页Drug Evaluation Research

摘　　要：不宁腿综合征为临床常见中枢神经系统感觉运动障碍性疾病,发病机制尚不明确,可能与遗传因素或多巴胺能系统功能失调有关。加巴喷丁恩那卡比最初由美国Xeno Port公司研发,之后由英国葛兰素史克公司通过并购获得,临床试验验证了其治疗不宁腿综合征的有效性。综述了加巴喷丁恩那卡比的研发背景、合成方法、药理学、药动学、临床评价、安全性和耐受性等研究进展,以期为临床上更好地应用提供依据。Restless legs syndrome （RLS） is a common clinical sensorimotor nervous system disorders. Its pathogenesis is uncertain and may be related to genetic factors or dopaminergic system dysfunction. Gabapentin enacarbil originally developed by the US company XenoPort, later was obtained by British GlaxoSmithKline through acquisitions, and clinical trials show the effectiveness of the treatment of RLS. This paper reviewed the research background, synthesis methods, pharmacology, pharmacokinetics, clinical evaluation, safety and tolerability of gabapentin enacarbil and provide the basis for better application in clinic.

关 键 词：不宁腿综合征 神经系统 运动障碍 加巴喷丁恩那卡比 

分 类 号：R282.710.5[医药卫生—中药学]